GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AEON Biopharma Inc (AMEX:AEON) » Definitions » Asset Turnover

AEON Biopharma (AEON Biopharma) Asset Turnover : 0.00 (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is AEON Biopharma Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. AEON Biopharma's Revenue for the three months ended in Mar. 2024 was $0.00 Mil. AEON Biopharma's Total Assets for the quarter that ended in Mar. 2024 was $4.94 Mil. Therefore, AEON Biopharma's Asset Turnover for the quarter that ended in Mar. 2024 was 0.00.

Asset Turnover is linked to ROE % through Du Pont Formula. AEON Biopharma's annualized ROE % for the quarter that ended in Mar. 2024 was 268.66%. It is also linked to ROA % through Du Pont Formula. AEON Biopharma's annualized ROA % for the quarter that ended in Mar. 2024 was -9,559.02%.


AEON Biopharma Asset Turnover Historical Data

The historical data trend for AEON Biopharma's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AEON Biopharma Asset Turnover Chart

AEON Biopharma Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Asset Turnover
0.03 0.04 - - -

AEON Biopharma Quarterly Data
Dec19 Jun20 Dec20 Jun21 Dec21 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of AEON Biopharma's Asset Turnover

For the Biotechnology subindustry, AEON Biopharma's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AEON Biopharma's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AEON Biopharma's Asset Turnover distribution charts can be found below:

* The bar in red indicates where AEON Biopharma's Asset Turnover falls into.



AEON Biopharma Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

AEON Biopharma's Asset Turnover for the fiscal year that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=0/( (10.778+6.845)/ 2 )
=0/8.8115
=0.00

AEON Biopharma's Asset Turnover for the quarter that ended in Mar. 2024 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Mar. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Mar. 2024 ))/ count )
=0/( (6.845+3.032)/ 2 )
=0/4.9385
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


AEON Biopharma  (AMEX:AEON) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

AEON Biopharma's annulized ROE % for the quarter that ended in Mar. 2024 is

ROE %**(Q: Mar. 2024 )
=Net Income/Total Stockholders Equity
=-472.072/-175.7125
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-472.072 / 0)*(0 / 4.9385)*(4.9385/ -175.7125)
=Net Margin %*Asset Turnover*Equity Multiplier
= %*0*-0.0281
=ROA %*Equity Multiplier
=-9,559.02 %*-0.0281
=268.66 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

AEON Biopharma's annulized ROA % for the quarter that ended in Mar. 2024 is

ROA %(Q: Mar. 2024 )
=Net Income/Total Assets
=-472.072/4.9385
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-472.072 / 0)*(0 / 4.9385)
=Net Margin %*Asset Turnover
= %*0
=-9,559.02 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


AEON Biopharma Asset Turnover Related Terms

Thank you for viewing the detailed overview of AEON Biopharma's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


AEON Biopharma (AEON Biopharma) Business Description

Traded in Other Exchanges
N/A
Address
4040 MacArthur Boulevard, Suite 260, Newport Beach, CA, USA, 92660
AEON Biopharma Inc is a clinical stage biopharmaceutical company focused on developing of its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA) injection for therapeutic indications.
Executives
Strathspey Crown Holdings Group, Llc 10 percent owner 4040 MACARTHUR BLVD., SUITE 210, NEWPORT BEACH CA 92660
Priveterra Sponsor, Llc 10 percent owner 300 SE 2ND STREET, SUITE 600, FORT LAUDERDALE FL 33301
Daewoong Co., Ltd 10 percent owner 244, GALMACHI-RO, JUNGWON-GU, SEONGNAM-SI, GYEONGGI-DO M5 13211
Alexander Blair Wilson officer: Exec VP, CLO & Corp Secretary 5 PARK PLAZA, SUITE 1750, IRVINE CA 92614
Chad Oh officer: Chief Medical Officer C/O AEON BIOPHARMA, INC., 4040 MACARTHUR BOULEVARD, SUITE 250, NEWPORT BEACH CA 92660
Marc Forth director, officer: Chief Executive Officer C/O AEON BIOPHARMA, INC., 4040 MACARTHUR BLVD., SUITE 260, NEWPOER BEACH CA 92660
Jost Fischer director C/O AEON BIOPHARMA, INC., 4040 MACARTHUR BOULEVARD, SUITE 250, NEWPORT BEACH CA 92660
Oleg Grodnensky 10 percent owner 300 SE 2ND STREET, SUITE 600, FORT LAUDERDALE FL 33301
Vikram Malik 10 percent owner 17901 VON KARMAN AVENUE, SUITE 150, IRVINE CA 92614
Peter A Reynolds officer: Chief Financial Officer 27442 PORTOLA PARKWAY, SUITE 200, FOOTHILL RANCH CA 92610
Robert J Palmisano director, 10 percent owner 110 HARTWELL AVENUE, LEXINGTON MA 02173
Shelley B Thunen director C/O RXSIGHT, INC., 100 COLUMBIA, ALISO VIEJO CA 92656
Eric G Carter director C/O KING PHARMACEUTICALS, INC., 501 FIFTH STREET, BRISTOL TN 37620
Plc Barclays 10 percent owner 1 CHURCHILL PLACE, CANARY WHARF, LONDON X0 E14 5HP
David Meredith officer: Chief Legal Officer&Secretary 300 SE 2ND STREET, SUITE 600, FORT LAUDERDALE FL 33301